Bristol-Myers Squibb sells Oncology Therapeutics Network

Share this article:
Bristol-Myers Squibb (BMS) has signed an agreement to sell its Oncology Therapeutics Network (OTN) to investment firm One Equity Partners for an unspecified amount.
BMS said it expects the deal to be complete during the first quarter of 2005, pending regulatory approvals.
The company did not disclose terms of the deal or provide further product plans.
The divestiture will enable BMS to focus on strategic priorities in developing its pipeline and new product opportunities in ten disease areas of significant unmet medical need, the drug maker said.
OTN is a specialty distributor of pharmaceuticals to office-based oncologists.
In 2003, OTN generated revenues of $2.2 billion in earnings before minority interest and taxes of $14 million.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.